PULSION receives CE certification for PiCCO2

CE certification marks the signal for commercialization in EU / More than 150 orders / Delivery to leading hospitals initiated

München, (PresseBox) - PULSION Medical Systems AG, the market leader for minimal invasive cardiovascular monitoring systems, received the CE certification for the new monitoring generation PiCCO2 and began its implementation in leading hospitals across Europe. PiCCO2 was introduced to the public in March and promises to carry PiCCO’s success story into the future. The maintenance of oxygen supply to the organs is the main objective of Intensive care and emergency medicine.

Any gain of time through earlier, on-target therapeutic decisions can save lives. Improved survival rates, shortened ventilation times and intensive care stay, resulting in reduced costs, were shown through the utilization of different parameters for patient monitoring. PiCCO2 combines these possibilities, freeing opportunities to improve patient care as well as cost-efficiency.

The simple, intuitive handling and the new ergonomic display of parameters enable the user to benefit from the powerful functions of the PiCCO2 in a fast, simple and flexible way.

“The feedback from our clients regarding the new product generation is overwhelming. More than 150 orders, even before an opportunity to the test the product, make for a strong statement. The delivery of the devices has commenced this week. We will keep this pace up and there is more to come”, said Bradley Gould, CEO of PULSION Medical Systems AG.

PULSION Medical Systems SE

PULSION Medical Systems AG, founded in 1990, has become one of the leading specialists for intelligent medical diagnosis and therapy management systems and has been listed on the Stock Exchange in Frankfurt since 2001. The repeated development of innovative product lines in the medtech field is the basis for creation and expansion of the attractive disposable business with sterile products and pharmaceuticals.

The business unit PULSION Critical Care covering intensive care medicine, perioperative medicine and emergency medicine focuses on the management of cardiovascular and organ functions of critically ill patients. Products and activities of the business unit PULSION Perfusion are directed at the diagnosis and therapy management of organ and tissue perfusion in ophthalmology, surgery and hepatology.

PULSION products are marketed worldwide via own sales channels or secondary distribution. All products are certified with the CE mark which is basis for marketing in the EU and some other countries. The US-American FDA approval and the Japanese market approval have been issued for selected product lines.

Further information about PULSION is available at www.pulsion.com.

PULSION Medical Systems AG
ISIN DE0005487904 Equity capital: Euro 9,577,302 divided into no-par-value euro 1 individual share certificates

Diese Pressemitteilungen könnten Sie auch interessieren

Weitere Informationen zum Thema "Medizintechnik":

Steigende Cyber-Angriffe durch Künstliche Intelligenz

Avast, Her­s­tel­ler von di­gi­ta­len Si­cher­heit­s­pro­duk­ten, hat den Si­cher­heits­re­port für 2018 vor­ge­s­tellt. Dar­aus geht her­vor, dass in die­sem Jahr ver­stärkt ei­ne Kom­bi­na­ti­on aus neu­en und tra­di­tio­nel­len Si­cher­heits­be­dro­hun­gen auf­t­re­ten wird, dar­un­ter auch ers­te An­grif­fe, die auf Künst­li­cher In­tel­li­genz ba­sie­ren.


News abonnieren

Mit dem Aboservice der PresseBox, erhalten Sie tagesaktuell und zu einer gewünschten Zeit, relevante Presseinformationen aus Themengebieten, die für Sie interessant sind. Für die Zusendung der gewünschten Pressemeldungen, geben Sie bitte Ihre E-Mail-Adresse ein.

Es ist ein Fehler aufgetreten!

Vielen Dank! Sie erhalten in Kürze eine Bestätigungsemail.

Ich möchte die kostenlose Pressemail abonnieren und habe die Bedingungen hierzu gelesen und akzeptiert.